EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Unveiling citicoline's mechanisms and clinical relevance in the treatment of neuroinflammatory disorders

Simona Cavalu iD, Sameh Saber iD, Asmaa Ramadan, Elsayed A Elmorsy iD, Rabab S Hamad iD, Mustafa Ahmed Abdel-Reheim iD, Mahmoud E Youssef iD

The FASEB Journal · 2024-09 · 38 (17)

DOI: 10.1096/fj.202400823r ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The FASEB Journal, online erschienen am 02.09.2024. Verfasst von Simona Cavalu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania. Hauptthemen laut MEDLINE: Cytidine Diphosphate Choline, Neuroinflammatory Diseases. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 185 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Citicoline, a compound produced naturally in small amounts in the human body, assumes a pivotal role in phosphatidylcholine synthesis, a dynamic constituent of membranes of neurons. Across diverse models of brain injury and neurodegeneration, citicoline has demonstrated its potential through neuroprotective and anti‐inflammatory effects. This review aims to elucidate citicoline's anti‐inflammatory mechanism and its clinical implications in conditions such as ischemic stroke, head trauma, glaucoma, and age‐associated memory impairment. Citicoline's anti‐inflammatory prowess is rooted in its ability to stabilize cellular membranes, thereby curbing the excessive release of glutamate—a pro‐inflammatory neurotransmitter. Moreover, it actively diminishes free radicals and inflammatory cytokines productions, which could otherwise harm neurons and incite neuroinflammation. It also exhibits the potential to modulate microglia activity, the brain's resident immune cells, and hinder the activation of NF‐κB, a transcription factor governing inflammatory genes. Clinical trials have subjected citicoline to rigorous scrutiny in patients grappling with acute ischemic stroke, head trauma, glaucoma, and age‐related memory impairment. While findings from these trials are mixed, numerous studies suggest that citicoline could confer improvements in neurological function, disability reduction, expedited recovery, and cognitive decline prevention within these cohorts. Additionally, citicoline boasts a favorable safety profile and high tolerability. In summary, citicoline stands as a promising agent, wielding both neuroprotective and anti‐inflammatory potential across a spectrum of neurological conditions. However, further research is imperative to delineate the optimal dosage, treatment duration, and underlying mechanisms. Moreover, identifying specific patient subgroups most likely to reap the benefits of citicoline as a new therapy remains a critical avenue for exploration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytidine Diphosphate CholineNeuroinflammatory DiseasesHumansAnimalsNeuroprotective AgentsNootropic AgentsAnti-Inflammatory AgentsClinical Relevance

Stichwörter der Autor:innen

CNS disorderscell signalingciticolineneuroinflammationnew therapies

Substanzen

Cytidine Diphosphate CholineNeuroprotective AgentsNootropic AgentsAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania.
  • Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt.
  • Department of Biochemistry, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt.
  • Department of Pharmacology and Therapeutics, College of Medicine, Qassim University, Buraidah, Saudi Arabia.
  • Biological Sciences Department, College of Science, King Faisal University, Al Ahsa, Saudi Arabia.
  • Central Laboratory, Theodor Bilharz Research Institute, Giza, Egypt.

ORCID-Profile: Simona Cavalu, Sameh Saber, Elsayed A Elmorsy, Rabab S Hamad, Mustafa Ahmed Abdel-Reheim, Mahmoud E Youssef

Zitieren

APA

Cavalu, S., Saber, S., Ramadan, A., Elmorsy, E. A., Hamad, R. S., Abdel-Reheim, M. A., & Youssef, M. E. (2024). Unveiling citicoline's mechanisms and clinical relevance in the treatment of neuroinflammatory disorders. The FASEB Journal, 38(17). https://doi.org/10.1096/fj.202400823r

Vancouver

Cavalu S, Saber S, Ramadan A, Elmorsy EA, Hamad RS, Abdel-Reheim MA, et al. Unveiling citicoline's mechanisms and clinical relevance in the treatment of neuroinflammatory disorders. The FASEB Journal. 2024;38(17). doi:10.1096/fj.202400823r

BibTeX
@article{Cavalu2024,
  author = {Cavalu, Simona and Saber, Sameh and Ramadan, Asmaa and Elmorsy, Elsayed A and Hamad, Rabab S and Abdel-Reheim, Mustafa Ahmed and Youssef, Mahmoud E},
  title = {Unveiling citicoline's mechanisms and clinical relevance in the treatment of neuroinflammatory disorders},
  journal = {The FASEB Journal},
  year = {2024},
  volume = {38},
  number = {17},
  doi = {10.1096/fj.202400823r}
}
Kostenlos starten →